Julia Rotow
YOU?
Author Swipe
View article: Supplementary Table S4 from Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of <i>EGFR</i>-Mutant and <i>RET</i> Fusion-Positive Lung Cancers
Supplementary Table S4 from Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of <i>EGFR</i>-Mutant and <i>RET</i> Fusion-Positive Lung Cancers Open
Adverse events observed with combination therapy
View article: Supplementary Table S3 from Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of <i>EGFR</i>-Mutant and <i>RET</i> Fusion-Positive Lung Cancers
Supplementary Table S3 from Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of <i>EGFR</i>-Mutant and <i>RET</i> Fusion-Positive Lung Cancers Open
Combination therapy dosing
View article: Supplementary Table S5 from Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of <i>EGFR</i>-Mutant and <i>RET</i> Fusion-Positive Lung Cancers
Supplementary Table S5 from Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of <i>EGFR</i>-Mutant and <i>RET</i> Fusion-Positive Lung Cancers Open
Dose modification
View article: Supplementary Table S1 from Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of <i>EGFR</i>-Mutant and <i>RET</i> Fusion-Positive Lung Cancers
Supplementary Table S1 from Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of <i>EGFR</i>-Mutant and <i>RET</i> Fusion-Positive Lung Cancers Open
Enrollment assay
View article: Supplementary Table S8 from Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of <i>EGFR</i>-Mutant and <i>RET</i> Fusion-Positive Lung Cancers
Supplementary Table S8 from Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of <i>EGFR</i>-Mutant and <i>RET</i> Fusion-Positive Lung Cancers Open
Combination therapy efficacy
View article: Supplementary Figure S2 from Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of <i>EGFR</i>-Mutant and <i>RET</i> Fusion-Positive Lung Cancers
Supplementary Figure S2 from Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of <i>EGFR</i>-Mutant and <i>RET</i> Fusion-Positive Lung Cancers Open
Durable combination therapy benefit
View article: Data from First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC
Data from First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC Open
Purpose:First-line treatment options for MET exon 14 skipping–mutant metastatic non–small cell lung cancer vary because of differences in drug approvals and clinical experience. This study investigates factors influencing outcomes w…
View article: Supplementary Figure 5 from First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC
Supplementary Figure 5 from First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC Open
Supplementary Figure 5
View article: Supplementary Figure 9 from First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC
Supplementary Figure 9 from First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC Open
Supplementary Figure 9
View article: Supplementary Figure 3 from First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC
Supplementary Figure 3 from First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC Open
Supplementary Figure 3
View article: Supplementary Figure 7 from First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC
Supplementary Figure 7 from First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC Open
Supplementary Figure 7
View article: Supplementary Figure 2 from First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC
Supplementary Figure 2 from First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC Open
Supplementary Figure 2
View article: Supplementary Figure 4 from First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC
Supplementary Figure 4 from First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC Open
Supplementary Figure 4
View article: Supplementary Figure 1 from First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC
Supplementary Figure 1 from First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC Open
Supplementary Figure 1
View article: Supplementary Figure 6 from First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC
Supplementary Figure 6 from First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC Open
Supplementary Figure 6
View article: Supplementary Figure 8 from First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC
Supplementary Figure 8 from First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC Open
Supplementary Figure 8
View article: First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC
First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC Open
Purpose: First-line treatment options for MET exon 14 skipping–mutant metastatic non–small cell lung cancer vary because of differences in drug approvals and clinical experience. This study investigates factors influencing outcomes with fi…
View article: Plasma epigenomic profiling reveals treatment-emergent squamous transformation in prostate cancer
Plasma epigenomic profiling reveals treatment-emergent squamous transformation in prostate cancer Open
View article: Mitigation and management of adverse events associated with amivantamab therapy
Mitigation and management of adverse events associated with amivantamab therapy Open
Amivantamab is a fully human bispecific epidermal growth factor receptor (EGFR)–directed and mesenchymal epithelial transition (MET) receptor–directed antibody. Intravenous amivantamab is approved and recommended by treatment guidelines as…
View article: Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors Open
View article: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors Open
For patients with advanced non-small-cell lung cancer (NSCLC), dual immune checkpoint blockade (ICB) with CTLA4 inhibitors and PD-1 or PD-L1 inhibitors (hereafter, PD-(L)1 inhibitors) is associated with higher rates of anti-tumour activity…
View article: Data from Osimertinib and selpercatinib efficacy, safety, and resistance in a multicenter, prospectively treated cohort of EGFR-mutant and RET fusion-positive lung cancers
Data from Osimertinib and selpercatinib efficacy, safety, and resistance in a multicenter, prospectively treated cohort of EGFR-mutant and RET fusion-positive lung cancers Open
Purpose: Acquired RET fusions have been reported at resistance to treatment with EGFR inhibitors in EGFR-mutant non-small cell lung cancer (NSCLC), however, a multicenter cohort of patients with EGFR-mutant lung cancers treated with osimer…
View article: Supplementary Table S2 from Osimertinib and selpercatinib efficacy, safety, and resistance in a multicenter, prospectively treated cohort of EGFR-mutant and RET fusion-positive lung cancers
Supplementary Table S2 from Osimertinib and selpercatinib efficacy, safety, and resistance in a multicenter, prospectively treated cohort of EGFR-mutant and RET fusion-positive lung cancers Open
Prior tyrosine kinase inhibitor (TKI) therapy details
View article: Supplementary Figure S1 from Osimertinib and selpercatinib efficacy, safety, and resistance in a multicenter, prospectively treated cohort of EGFR-mutant and RET fusion-positive lung cancers
Supplementary Figure S1 from Osimertinib and selpercatinib efficacy, safety, and resistance in a multicenter, prospectively treated cohort of EGFR-mutant and RET fusion-positive lung cancers Open
Patient Cohort Identification
View article: Supplementary Table S3 from Osimertinib and selpercatinib efficacy, safety, and resistance in a multicenter, prospectively treated cohort of EGFR-mutant and RET fusion-positive lung cancers
Supplementary Table S3 from Osimertinib and selpercatinib efficacy, safety, and resistance in a multicenter, prospectively treated cohort of EGFR-mutant and RET fusion-positive lung cancers Open
Combination therapy dosing
View article: Supplementary Table S1 from Osimertinib and selpercatinib efficacy, safety, and resistance in a multicenter, prospectively treated cohort of EGFR-mutant and RET fusion-positive lung cancers
Supplementary Table S1 from Osimertinib and selpercatinib efficacy, safety, and resistance in a multicenter, prospectively treated cohort of EGFR-mutant and RET fusion-positive lung cancers Open
Enrollment assay
View article: Supplementary Table S6 from Osimertinib and selpercatinib efficacy, safety, and resistance in a multicenter, prospectively treated cohort of EGFR-mutant and RET fusion-positive lung cancers
Supplementary Table S6 from Osimertinib and selpercatinib efficacy, safety, and resistance in a multicenter, prospectively treated cohort of EGFR-mutant and RET fusion-positive lung cancers Open
Dose discontinuation
View article: Supplementary Table S3 from Osimertinib and selpercatinib efficacy, safety, and resistance in a multicenter, prospectively treated cohort of EGFR-mutant and RET fusion-positive lung cancers
Supplementary Table S3 from Osimertinib and selpercatinib efficacy, safety, and resistance in a multicenter, prospectively treated cohort of EGFR-mutant and RET fusion-positive lung cancers Open
Combination therapy dosing
View article: Supplementary Table S4 from Osimertinib and selpercatinib efficacy, safety, and resistance in a multicenter, prospectively treated cohort of EGFR-mutant and RET fusion-positive lung cancers
Supplementary Table S4 from Osimertinib and selpercatinib efficacy, safety, and resistance in a multicenter, prospectively treated cohort of EGFR-mutant and RET fusion-positive lung cancers Open
Adverse events observed with combination therapy
View article: Supplementary Table S8 from Osimertinib and selpercatinib efficacy, safety, and resistance in a multicenter, prospectively treated cohort of EGFR-mutant and RET fusion-positive lung cancers
Supplementary Table S8 from Osimertinib and selpercatinib efficacy, safety, and resistance in a multicenter, prospectively treated cohort of EGFR-mutant and RET fusion-positive lung cancers Open
Combination therapy efficacy